thiotepa / Generic mfg.  >>  Phase N/A
Welcome,         Profile    Billing    Logout  

8 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
thiotepa / Generic mfg.
NCT03609840: Study of Thiotepa and TEPA Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients

Completed
N/A
25
US
Thiotepa, Alkylating antineoplastic agent, Tepadina
University of California, San Francisco
Hematologic Malignancies, Nonmalignant Diseases, Immune Deficiency, Hemoglobinopathies, Genetic Inborn Errors of Metabolism, Fanconi Anemia, Thalassemia, Sickle Cell Disease
07/23
07/23
NCT01505569: Auto Transplant for High Risk or Relapsed Solid or CNS Tumors

Completed
N/A
44
US
Ifosfamide, Mitoxana, Ifex, Etoposide, Eposin, Etopophos, Vepesid, VP-16, Mesna, Uromitexan, Mesnex, G-CSF, Granulocyte colony-stimulating factor, Busulfan, Busulfex, Melphalan, 50 mg/m2 IV over 30 min, Thiotepa, Thioplex, Autologous stem cell infusion, Radiation, Carboplatin, Paraplatin, Paclitaxel, Taxol, Onxal, Leukapheresis, Anti-seizure prophylaxis, Ursodiol
Masonic Cancer Center, University of Minnesota
Ewing's Family Tumors, Renal Tumors, Hepatoblastoma, Rhabdomyosarcoma, Soft Tissue Sarcoma, Primary Malignant Brain Neoplasms, Retinoblastoma, Medulloblastoma, Supra-tentorial Primative Neuro-Ectodermal Tumor (PNET), Atypical Teratoid/Rhabdoid Tumor (AT/RT), CNS Tumors, Germ Cell Tumors
02/24
02/24
NCT06385808: Efficacy and Safety of MTBF Conditioning Regimen for Salvageable Allo-HSCT in the Treatment of R/R AML

Not yet recruiting
N/A
37
NA
MTBF regimen, Mitoxantrone Hydrochloride Liposome, Thiotepa, Busulfan, Fludarabine
First Affiliated Hospital Xi'an Jiaotong University
Relapse Leukemia, Refractory Acute Myeloid Leukemia, Conditioning, Hematopoietic Stem Cell Transplantation
12/26
12/26
NCT05854225: Thiotepa Incorporating TBI/Cy Conditioning Regimen for EBV-HLH With Central Nervous System Involvement

Recruiting
N/A
20
RoW
Thiotepa, TT
Beijing Friendship Hospital
HLH
06/24
01/25
NCT02880293: Haploidentical (Half-matched) Related Donor Stem Cell Transplantation Using Killer Immunoglobulin-like Receptors in Addition to Normal Selection Factors to Determine the Best Donor

Completed
N/A
44
US
melphalan, Alkeran®, fludarabine, FLUDARA®, thiotepa, Cyclophosphamide, Cytoxan®, Mesna, Mesnex®, Mycophenolate Mofetil, CellCept®, Filgrastim, Neupogen®, Tacrolimus, Prograf®
Memorial Sloan Kettering Cancer Center
Hematologic Malignancy
11/23
11/23
ChiCTR2200064864: A clinical study of haploid HSCT pretreated with citrate in the treatment of adult T-ALL

Recruiting
N/A
18
 
CCNU+Thiotepa+BU+CY
Hematology Medical Center, Second Affiliated Hospital of Army Medical University; Second Affiliated Hospital of Army Medical University, The Second Affiliated Hospital of Army Military Medical University set up a new clinical technology project
T-cell acute lymphocytical leukemia (T-ALL)
 
 
NCT06111612: Intensive Conditioning With Thiotepa Combined With Bu/Flu/Ara-C in Allo-HSCT for Myeloid Malignancies With Extramedullary Involvement

Not yet recruiting
N/A
50
NA
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Acute Myeloid Leukemia, Myelodysplastic Neoplasm, Chronic Myelomonocytic Leukemia, Myeloid Sarcoma, Extramedullary Myeloid Tumor
01/26
01/27
ChiCTR2300074726: Study of the TBFC/V regimen (thiotepa combined with busulfan, fludarabine and cyclophosphamide (TBFC) or thiotepa combined with busulfan, fludarabine and venetoclax (TBFV) in a pretreatment regimen for allogeneic haematopoietic stem cell transplantation

Recruiting
N/A
30
 
NA ;NA
The First Affiliated Hospital of Ningbo University; Department of Hematology, self-funding
Malignant hematology disease
 
 

Download Options